ERBB2 and triple-negative breast carcinoma: Tumor subtypes were distributed as follows: Luminal A (122 cases, 35.6%), Luminal B (126 cases, 36.7%), HER2 positive (66 cases, 19.2%), and triple-negative breast cancer (TNBC) (27 cases, 7.9%), with 2 cases (0.6%) having unknown subtypes.